Interleukin-1β as emerging therapeutic target in hematological malignancies and potentially in their complications

Autor: Alicia Villatoro, Maria del Mar Arriero, Lorena Arranz
Jazyk: angličtina
Rok vydání: 2017
Předmět:
0301 basic medicine
VDP::Medical disciplines: 700::Clinical medical disciplines: 750::Hematology: 775
medicine.drug_class
medicine.medical_treatment
VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Hematologi: 775
Autoimmune diseases
Interleukin-1beta
Drug Evaluation
Preclinical
Pain
Antineoplastic Agents
Inflammation
Preclinical models
03 medical and health sciences
0302 clinical medicine
medicine
Animals
Humans
Molecular Targeted Therapy
Bone
Pathological
Autoimmune disease
business.industry
Hematology
medicine.disease
Receptor antagonist
Hematopoietic malignancies
Interleukin-1β
Hematopoiesis
Interleukin 1β
Disease Models
Animal
Haematopoiesis
030104 developmental biology
Cytokine
Oncology
Hematologic Neoplasms
T cell subset
Immunology
Cytokines
Inflammation Mediators
medicine.symptom
business
Signal Transduction
030215 immunology
ISSN: 0268-960X
Popis: Interleukin-1β (IL-1β) is a pleiotropic cytokine that exerts multiple roles in both physiological and pathological conditions. It is produced by different cell subsets, and drives a wide range of inflammatory responses in numerous target cells. Enhanced IL-1β signaling is a common event in patients of hematological malignancies. Recent body of evidence obtained in preclinical models shows the pathogenic role of these alterations, and the promising therapeutic value of IL-1 targeting. In this review, we further highlight a potential contribution of IL-1β linking to complications and autoimmune disease that should be investigated in future studies. Hence, drugs that target IL-1 may be helpful to improve outcome or reduce morbidity in patients. Some of them are FDA-approved, and used efficiently against autoimmune diseases, like IL-1 receptor antagonist. In the clinic, however, this agent seems to have limited properties. Current improved drugs will allow to determine the true potential of IL-1 and IL-1β targeting as therapy in hematological malignancies and their related complications.
Databáze: OpenAIRE
Externí odkaz: